Fresenius Medical Care, the world’s leading provider of products and services for people with kidney disease, is now marketing the “Seraph 100 Microbind Affinity Blood Filter” adsorber from ExThera Medical in several European countries. It is used in intensive care medicine for the extracorporeal removal of pathogens from the bloodstream.
The “Seraph 100” adsorber is used in intensive care medicine for the extracorporeal removal of pathogens from the bloodstream and can be operated with acute dialysis machines from Fresenius Medical Care. Similar to dialysis, the blood is pumped through the filter and purified in the process.
The device has been CE-marked since 2019 for the reduction of pathogens in bloodstream infections, in addition to therapy with anti-infectives.Fresenius Medical Care and ExThera Medical have signed an agreement under which the world’s leading provider of products and services for people with kidney disease will distribute the adsorber in Belgium, Denmark, France, Germany, Italy, Luxembourg, the Netherlands, Norway, Sweden and the United Kingdom. With the innovative adsorber technology from ExThera Medical, Fresenius Medical Care is strengthening its offering in the field of intensive care solutions. Blood infections often lead to kidney, lung, or multiple organ failure.
Treatment with Seraph 100 can eliminate more than 90 percent of the pathogens in the patient’s blood with each pass of the filter. Initial treatment results in Covid-19 patients are also promising.
Source: “Fresenius Medical Care expands range for intensive care medicine with adsorber “Seraph 100″ from Exthera Medical”, 07.01.2021
CARDIOVASC 2021; 20(2): 32
